Daxor (NASDAQ:DXR) & Co-Diagnostics (NASDAQ:CODX) Head to Head Contrast

Co-Diagnostics (NASDAQ:CODX) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Risk and Volatility

Co-Diagnostics has a beta of -0.84, suggesting that its stock price is 184% less volatile than the S&P 500. Comparatively, Daxor has a beta of -0.54, suggesting that its stock price is 154% less volatile than the S&P 500.

Valuation & Earnings

This table compares Co-Diagnostics and Daxor”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$6.81 million	5.06	-$35.33 million	($1.38)	-0.78
Daxor	N/A	N/A	N/A	N/A	N/A

Daxor has lower revenue, but higher earnings than Co-Diagnostics.

Insider and Institutional Ownership

15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 6.1% of Co-Diagnostics shares are held by insiders. Comparatively, 59.0% of Daxor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Co-Diagnostics and Daxor, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	0	1	0	0	2.00
Daxor	0	0	1	0	3.00

Co-Diagnostics presently has a consensus target price of $1.50, suggesting a potential upside of 38.89%. Daxor has a consensus target price of $24.75, suggesting a potential upside of 180.61%. Given Daxor’s stronger consensus rating and higher probable upside, analysts plainly believe Daxor is more favorable than Co-Diagnostics.

Profitability

This table compares Co-Diagnostics and Daxor’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-563.93%	-54.94%	-49.28%
Daxor	N/A	N/A	N/A

Summary

Daxor beats Co-Diagnostics on 8 of the 10 factors compared between the two stocks.

About Co-Diagnostics

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.